Skip to Content
MilliporeSigma

Key Documents

View All Documentation

Skip To

SML2710

ZCZ011

≥98% (HPLC)

Synonym(s):

6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole, 6-Methyl-3-[2-nitro-1-(2-thienyl)ethyl]-2-phenyl-1H-indole, ZCZ 011, ZCZ-011

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice
5 mg

Available to ship TODAYfromMILWAUKEE

$91.10
25 mg
Check Cart for Availability
$370.00

About This Item

Empirical Formula (Hill Notation):
C21H18N2O2S
CAS Number:
1998197-39-9
Molecular Weight:
362.44
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD31692973
Assay:
≥98% (HPLC)
Form:
powder

$91.10

Available to ship TODAYDetails

​
Request a Custom Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Segment

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[s]1c(ccc1)C(C[N+](=O)[O-])c2c3c([nH]c2c4ccccc4)cc(cc3)C

InChI key

RJSPNRDBWHHFMH-UHFFFAOYSA-N

Biochem/physiol Actions

Brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that blocks neuropathic pain without cannabimimetic side-effects.
ZCZ011 is a brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that enhances orthosteric agonist CP55,940, while reduces orthosteric inverse agonist SR141716A, CB1 binding. ZCZ011 potentiates AEA-stimulated GTPγS binding (Emax = 46.5% without vs. 115.2% with 100 nM ZCZ011; mouse brain membranes) and cellular signaling (β-arrestin Emax = 100% without vs.157% with 100 nM ZCZ011, pERK pIC50 = 6.5 without vs. 8.3 with 10 nM ZCZ011; hCB1 cells). ZCZ011 exhibits antinociceptive efficay in murine chronic constriction injury (CCI) model of neuropathic pain & carrageenan model of inflammatory pain (40 mg/kg i.p.) without cannabimimetic side-effects.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML1926SML1886S1697
ZCZ011 ≥98% (HPLC)

Sigma-Aldrich

SML2710

ZCZ011

GAT211 ≥98% (HPLC)

Sigma-Aldrich

SML1926

GAT211

VPC-13566 ≥98% (HPLC)

Sigma-Aldrich

SML1886

VPC-13566

SPD304 ≥98% (HPLC), solid

Sigma-Aldrich

S1697

SPD304

description

≥98% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC), solid

form

powder

form

powder

form

powder

form

solid

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 10 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

H2O: >5 mg/mL

color

white to beige

color

white to beige

color

white to beige

color

white

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Questions

  1. Does it specifically target the CB1 receptor?

    1 answer

    1. As shown on the product detail page, Product ZCZ011 is a brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that enhances orthosteric agonist CP55,940, while reduces orthosteric inverse agonist SR141716A, CB1 binding. ZCZ011 potentiates AEA-stimulated GTP?S binding (Emax = 46.5% without vs. 115.2% with 100 nM ZCZ011; mouse brain membranes) and cellular signaling (?-arrestin Emax = 100% without vs.157% with 100 nM ZCZ011, pERK pIC50 = 6.5 without vs. 8.3 with 10 nM ZCZ011; hCB1 cells). ZCZ011 exhibits antinociceptive efficay in murine chronic constriction injury (CCI) model of neuropathic pain & carrageenan model of inflammatory pain (40 mg/kg i.p.) without cannabimimetic side-effects.

      Identity testing is performed to be sure the product is ZCZ011 but test functions are not determined. The end-user may want to consult with literature to get more information about ZCZ011.

      Helpful?

Reviews

No rating value

Active Filters